News from Eisai Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

21 Jun, 2017, 08:02 ET Eisai Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study will Continue as Planned Based on Interim Safety Analysis by Independent Data Monitoring Committee (DMC)

Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as...


04 Jun, 2017, 08:30 ET Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC)

Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's...


03 Jun, 2017, 14:24 ET Further Study of Combination of Eisai's Lenvatinib and Merck's Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial

Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as...


31 May, 2017, 08:00 ET Eisai and Johns Hopkins Extend Drug Discovery Collaboration with New Licensing Agreement

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have...


30 May, 2017, 19:35 ET Eisai Enters into a New Joint Research Agreement with the Broad Institute to Develop an Antimalarial Medicine

Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that it has entered into a new joint research agreement with...


18 May, 2017, 07:55 ET Eisai Data at ASCO 2017 Annual Meeting Showcase Latest Results of Ongoing Research in Oncology

Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from...


27 Apr, 2017, 08:06 ET Meta-Analysis of Published Trials Supports the Extrapolation of Antiepileptic Drug Efficacy Data from Adult to Pediatric Patients with Primary Generalized Tonic-Clonic Seizures

Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive...


19 Apr, 2017, 08:00 ET Eisai Announces Continued Support of Initiatives for the Elimination of Lymphatic Filariasis

Eisai Inc. announced today that its parent company Tokyo, Japan-based Eisai Co., Ltd. has pledged the continuing support of its initiatives for the...


13 Apr, 2017, 08:06 ET Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual Meeting

Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a...


28 Mar, 2017, 07:55 ET Eisai to Present Clinical and Preclinical Research from Oncology Portfolio at 2017 AACR Annual Meeting

Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual...


23 Mar, 2017, 08:06 ET Eisai to Launch New Medikidz Epilepsy Comic Book at the National Walk for Epilepsy

Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the...


17 Mar, 2017, 08:00 ET Dr. Kirk Shepard appointed Senior Vice President, Global Medical Affairs of the Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice...


25 Jan, 2017, 08:00 ET Positive Topline Results of Large Phase 3 Trial Show Eisai's Lenvatinib Meets Primary Endpoint in Unresectable Hepatocellular Carcinoma

Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple...


18 Jan, 2017, 08:00 ET Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it is participating in Access Accelerated, a global...


04 Jan, 2017, 16:05 ET Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with...


19 Dec, 2016, 13:30 ET Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has...


12 Dec, 2016, 08:06 ET Eisai Presents Data on BACE Inhibitor Elenbecestat (E2609) at 9th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest...


05 Dec, 2016, 13:00 ET Eisai Announces Final Results from Phase 3 Open-Label Study of Rufinamide at American Epilepsy Society (AES) Annual Meeting

Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of...


05 Dec, 2016, 13:00 ET Eisai Announces New Analyses and Data on Perampanel at American Epilepsy Society (AES) Meeting

Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES)....


01 Dec, 2016, 08:00 ET Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice...


30 Nov, 2016, 11:39 ET New Data on Eribulin Mesylate Injection to Be Presented at the 2016 San Antonio Breast Cancer Symposium Explore Potential of Regimens in Treatment of Metastatic Breast Cancer

Eisai Inc. announced today the presentation of new data from studies of eribulin, marketed under the brand name Halaven®, at the 2016 San...


28 Nov, 2016, 09:41 ET New Data and Analyses on FYCOMPA and BANZEL at American Epilepsy Society Meeting Demonstrate Eisai's Continued Commitment to the Epilepsy Community

Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data...


17 Nov, 2016, 09:05 ET FDA Grants Fast Track Designation for Development of E2609, Eisai's BACE Inhibitor for Early Alzheimer's Disease

Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a...


03 Nov, 2016, 08:05 ET Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity...